Luye offers sweetest pill with $764m IPO
Luye Pharma Group has priced its HK$5.9bn ($764m) IPO at the top of the range, as the healthcare sector found favour among investors. But heavily subscribed books meant that some accounts ended up empty handed.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: